Asset profile
Mesdopetam (IRL790)
Small molecule
Evidence outlook · lead readout
NCT04435431 · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04435431: This was a randomized, quadruple-blind, placebo-controlled trial with 155 participants. Its primary clinical endpoint was the change in daily ON-time without troublesome dyskinesia; the reported changes were 1.211, 1.737, and 2.233 hours per day for mesdopetam 2.5, 5, and 7.5 mg versus 1.985 hours per day for placebo, but no p-value or confidence interval was reported, so whether the primary comparison was met is unclear.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.